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The paper in this edition by John Foekens’s group at the
Rotterdam Cancer Institute (Foekens et al, 1998) represents some-
thing of a landmark in the assessment of cathepsin D as a prog-
nostic marker in breast cancer. It demonstrates unequivocally that
cathepsin D is an independent marker of poor prognosis in all
groups of breast cancer patients.
Cathepsin D is an aspartyl protease that is normally localized
within lysosomes and is involved in protein catabolism and tissue
remodelling (Westley and May, 1996). For reasons that are not
clear, but probably as a result of intracellular misrouting, this
protease can be secreted. The secretion of cathepsin D is elevated
in some cancer cells, and it has been suggested that the illicit
secretion of a protease whose activity is normally restrained to the
intracellular degradation of proteins may facilitate the invasion
and spread of cancer cells.
Cathepsin D synthesis and secretion is regulated by oestrogen in
oestrogen-responsive breast cancer cells (Westley and Rochefort,
1980); however, the reason why cathepsin D is regulated by
oestrogen remains obscure. Given its role in protein catabolism, it
may be involved in tissue involution in oestrogen-responsive
tissues, and examples that immediately spring to mind are the
involution of ductal and alveolar structures in the breast following
the cessation of lactation and the post-partum involution of the
uterus. The regulation of cathepsin D expression by oestrogen
results from the interaction of the oestrogen receptor with
oestrogen response elements in the cathepsin D promoter. The
classical model of oestrogen action that involves the interaction of
receptor homodimers with a palindromic oestrogen response
element of the type found in the Xenopus laevis vitellogenin gene
promoter does not seem to apply to cathepsin D.
Cathepsin D expression originally became of clinical interest in
breast cancer as a potential marker of oestrogen responsiveness. It
was hoped that it would prove more reliable than existing markers
such as the oestrogen receptor; however, the promise of cathepsin
D as a marker of oestrogen responsiveness has not been fulfilled.
Interest in this protease has continued as a result of reports that it is
a marker of poor prognosis in node-negative breast cancer patients
(Spyratos et al, 1989; Foekens et al, 1996). The value of identi-
fying markers of poor prognosis in node-negative breast cancer is
that we need to be able to identify those women in this good-prog-
nosis group who are at significant risk of relapse and who would
be likely to benefit from a more aggressive treatment regimen.
Research into the prognostic value of cathepsin D has been
facilitated by the availability of a radiometric immunoassay that
has been validated by the EORTC Breast Cancer Cooperative
Group (Benraad et al, 1992). Although this assay is expensive to
perform, it measures the amount of cathepsin D in tumour cytosols
prepared for oestrogen receptor analysis with impressively low
inter-assay variation. It should be noted that at least three other
methods have been used to measure cathepsin D expression in
prognostic studies, namely Western transfer, immunohistochem-
istry and direct measurement of cathepsin D enzymatic activity.
While the quality control inherent in the radiometric assay is of
obvious benefit, pathology laboratories are increasingly called
upon to measure the expression of prognostic factors and generally
prefer immunohistochemical assays. These, although semiquanti-
tative, are able to provide potentially valuable information on
cellular localization. The development of a prognostically vali-
dated immunohistochemical assay for cathepsin D would undoubt-
edly bring cathepsin D closer to clinical relevance, in contrast to
its widely regarded current status as a research curiosity.
The major issue addressed by the paper of Foekens et al (1998)
is one that has been facing breast cancer patients, the clinicians
treating them and the pharmaceutical company involved in
producing the cathepsin D assay for more than 10 years, i.e. the
usefulness of cathepsin D as a prognostic marker to identify
women with a high risk of relapse. Evaluation of cathepsin D as a
prognostic marker has been seriously hampered both by the
numbers of patients included in the clinical studies (very few
studies have involved more than 150 patients) and by the relatively
short follow-up times (Westley and May, 1996). The study of
Foekens et al (1998) is remarkable in that it involved the analysis
of 2810 cytosolic extracts and the median follow-up time of
patients still alive at the time of the analysis was 88 months.
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Table 1 Effect of tumour cathepsin D on relative relapse and death rates
Cathepsin D status Relative relapse rate Relative death rate
Q2 vs Q1 1.27 (1.08–1.50) 1.36 (1.13–1.64)
Q3 vs Q1 1.45 (1.24–1.71) 1.52 (1.26–1.82)
Q4 vs Q1 1.48 (1.26–1.74) 1.56 (1.31–1.87)
Q1, 0–33; Q2, >33–47; Q3, 47–70; Q4, >70 pmol mg–1 protein.
Table 2 Effect of tumour cathepsin D on relapse-free and overall survival
Cathepsin D RFS Median RFS OS Median OS
status (% ± s.e.) (months) (% ± s.e.) (months)
Q1 55 ± 3 137 63 ± 2 156
Q2 48 ± 2 108 56 ± 2 134
Q3 42 ± 3 77 53 ± 2 127
Q4 36 ± 3 65 43 ± 3 101
Q1, 0–33; Q2, >33–47; Q3, 47–70; Q4, >70 pmol mg–1 protein. RFS, relapse-
free survival. OS, overall survival.The majority of the data were analysed by separating cathepsin
D levels into quartiles or by dichotomizing the data using a cut-off
value close to that of the median. Cathepsin D expression was not
associated with grade but was associated with menopausal, node,
oestrogen and progesterone receptor status as well as with age and
tumour size. These associations were weak but were statistically
significant because of the size of the study.
The major take-home message of the study of Foekens et al
(1998) is that cytosolic cathepsin D levels are predictive of early
relapse and survival not only in node-negative breast cancer
patients but in all subgroups of breast cancer patients examined.
This includes node-negative, node-positive, premenopausal and
post-menopausal patients. Multivariate analysis established that the
predictive value of cathepsin D was independent of the other
markers of prognosis examined. Of great significance was the
impact that cathepsin D expression was found to have on relapse-
free and overall survival. By multivariate analysis, relative relapse
rates increased up to 1.48 and relative death rates up to 1.56 when
comparing women with high and low levels of cathepsin D expres-
sion (Table 1). Survival analysis after 10 years of follow-up corrob-
orated the importance of cathepsin D measurement in predicting
relapse-free and overall survival. This analysis showed that there
was approximately a 20% difference in relapse-free and overall
survival probability between patients with the lowest (bottom 25%)
and highest (top 25%) expression of cathepsin D. Expressed in a
different way, median relapse-free survival dropped from 137 to 65
months and median overall survival dropped from 156 to 101
months with increasing cathepsin D expression (Table 2).
Clinical features such as nodal status are used to stratify patients
for treatment. Part of the attraction of cathepsin D as a prognostic
marker would be its value in predicting outcome within groups of
patients defined by nodal status. The use of cathepsin D to identify
node-negative patients with a high risk of relapse would have
considerable resource implications for treatment. Based on the
figures in the Foekens study, 10% of all patients would be targeted
for more aggressive therapy if node-negative women expressing
the highest levels (fourth quartile) were given additional therapy.
This figure would rise to 23% if all node-negative cases containing
more than the median value of 47 pmol mg–1 protein were
included. There is, as yet, no information available on the actual
benefit of such a strategy, and clinical trials would obviously be
required to answer this question.
The clear demonstration that elevated cathepsin D expression is
definitely associated with a poor prognosis raises some tantalizing
biological issues, some of which are addressed in the existing
cathepsin D literature. One issue that continues to resurface is that
of the cellular localization of the cathepsin D in breast tumours.
The original identification of cathepsin D as an oestrogen-regu-
lated protein was made using malignant breast epithelial cells in
tissue culture, and immunohistochemical studies have confirmed
that malignant epithelial cells in tumours make cathepsin D.
However, a number of immunohistochemical studies have ques-
tioned the assumption that it is the amount of cathepsin D in the
tumour cells that is of prognostic value and suggested that it is
expression in the stromal cells that is significant (O’Donaghue et
al, 1995; Nadji et al, 1996). This issue is important in under-
standing the biological role of cathepsin D in breast tumours,
because focusing on expression in stromal cells challenges the
assumption that tumour cells are responsible for their own inva-
sive potential. Another issue is that of secretion. Cathepsin D is
secreted from breast cancer cell lines, and this has considerable
mechanistic appeal because it could explain how a normally intra-
cellular protease could play its part in facilitating invasion and
metastasis. None of the current assays, however, is capable of
specifically measuring extracellular cathepsin D and, perversely,
immunohistochemical assays only assess intracellular cathepsin D
levels. There may, of couse, be a relationship between the amount
of intracellular and secreted cathepsin D, but it would be valuable
to try to measure the amount of this protease in the extracellular
space in tumours and to assess its prognostic value.
Finally, the question remains as to whether it is the proteolytic
activity of cathepsin D that it responsible for the poor prognosis. It
remains a possibility, for instance, that increased cathepsin D
could reflect a general oversupply of lysosomal proteases and that
some other protease is biologically more important. It has always
been difficult to rationalize the importance of cathepsin D when it
has such a low pH optimum, although it has been suggested that
the pH of a poorly vascularized tumour may be sufficiently acidic
to allow significant protease activity. Should cathepsin D become
a contender as a clinically important prognostic marker guiding
treatment, this issue would be highly relevant to oncologists
wishing to make decisions about the treatment of women with
high levels of cathepsin D in their tumours. If cathepsin D reflects
a poor prognosis without being involved biologically, then more
aggressive treatment could rely on the current repertoire of anti-
cancer treatments. If, however, it transpires that cathepsin D is
partially or wholly responsible for the aggressive behaviour of
tumours, then the development of specific inhibitors of this
enzyme would become increasingly urgent.
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